AMRX
AmnealANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Q1 execution was strong, with 4% revenue growth, 23% Specialty growth, adjusted EBITDA growth of 19%, and reaffirmed higher FY2026 guidance. Kashiv could add scale and diversification to biosimilars.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
A director reported an open-market sale of 34,819 shares at $12.94 on May 11, 2026; this is insider-activity context only, not evidence of operating performance. [#SEC-FORM4-2026-05-12]
Momentum
83
Value
64
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.25 · Bull $20.40 · Bear $15.17
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.25
Why
Momentum83 · Δ7d -7.1
Value64 · Δ7d -0.3
Sentiment47 · Δ7d -5.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
83
26% active weight
Current posture
7d trendFlat
Δ7d
-7.1
Δ21d
-11.2
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.1
Sentiment
47
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.7
Δ21d
-4.1
Why this grade
Composite grade A. Momentum 83.4 / Value 64.1 / Sentiment 46.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$5.7B
Beta
1.36
Shares Out
319.33M
P/E (TTM)
769.4
P/S (TTM)
1.36
P/FCF (TTM)
16.89
Rev YoY
+3.9%
EPS YoY
+403.5%
Gross Margin
+38.7%
Op Margin
+12.2%
Net Debt
$2.38B
Current Ratio
2.47
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology